Developer docs
API playgroundTry for free, no card

Search company profiles

ONCOTECH LTD

Full company profile

uuid028sy2p

Namestring
ONCOTECH LTD
Websiteurl
oncotech.global
Company typeenum
Private
Founded yearint
2019
Descriptiontext

OncoTech Ltd is a privately held UK-based company, founded in 2019 and headquartered in London. According to its firmographic profile, the company develops AI-based cancer screening technologies and oncology therapeutics, positioning it at the intersection of applied artificial intelligence and oncology drug development. The company maintains a web presence at oncotech.global, which targets a global audience via its top-level domain choice.

Beyond the high-level self-description, no verifiable information was available regarding OncoTech's specific product portfolio, underlying technology architecture, intellectual property holdings, funding history, management team, partnership network, customer base, revenue model, pricing, certifications, regulatory milestones, headcount, or go-to-market strategy. The company's own website (oncotech.global) was non-functional at the time of data collection, displaying only a loader/verification screen, and third-party data sources did not return substantive corporate, financial, or operational information. This combination of signals — a non-functional primary web presence combined with the absence of any corroborating data on funding, personnel, customers, or pipeline assets — implies either a very early/pre-commercial stage of development, limited public disclosure, or potential dormancy, and any investment-grade assessment will require primary-source verification of capitalization, pipeline status, and operational activity before substantive judgments can be made.

Short descriptiontext

OncoTech Ltd is a London-based private company founded in 2019 that develops AI-based cancer screening technologies and oncology therapeutics. Public information on its products, operations, and commercialization is severely limited.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
AI cancer screening, oncology therapeutics, cancer diagnostics, medical AI software, precision oncology
Industry3 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAB
Medical Oncology
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Pharmaceutical Preparations2834
Product category
Oncology AI Software
Social media profiles1 record
Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

OncoTech develops AI-based cancer screening technologies and oncology therapeutics. The company combines artificial intelligence with oncology to enable early cancer detection and advance therapeutic development for cancer patients.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1AI-based cancer screening technology
CategoryCancer Diagnostics / AI Software
Description

Artificial intelligence-based cancer screening technology for early cancer detection, targeting healthcare providers and oncology stakeholders.

2Oncology therapeutics
CategoryOncology Therapeutics
Description

Oncology therapeutics developed by OncoTech for cancer treatment, targeting oncology patients and healthcare providers.

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI biotech combining federated learning, diagnostics, and therapeutic development in oncology — closely aligned with OncoTech's positioning in Europe and its dual focus.

TypeDirect peer
Description

AI pathology platform focused on cancer diagnostics and biomarker discovery, partnering with pharma for therapeutic development — closely aligned with OncoTech's dual screening + therapeutics scope.

TypeDirect peer
Description

AI company applying deep learning to pathology and cancer diagnostics, with FDA-authorized products — a direct comparable for AI-based cancer screening technology.

4Tempus AI
TypeDirect peer
Description

AI-driven precision medicine company combining multimodal data, diagnostics, and therapeutic insights in oncology — directly comparable to OncoTech's AI cancer screening and oncology therapeutics focus.

TypeBroad incumbent
Description

Established leader in oncology molecular profiling and companion diagnostics, owned by Roche; represents the scaled incumbent in cancer screening/diagnostics that AI-driven players compete against.

TypeBroad incumbent
Description

Public diagnostics company with cancer screening products (Cologuard, Oncotype); represents an established incumbent in cancer screening that any AI-driven screening entrant must differentiate against.

TypeDirect peer
Description

AI-driven drug discovery company with oncology pipeline, merged with Recursion — comparable for combining AI technology platform with proprietary therapeutic programs.

TypeDirect peer
Description

AI-native biopharma applying machine learning to drug discovery across oncology and other areas; comparable for its combination of AI technology platform with therapeutic development.

9GRAIL
TypeBroad incumbent
Description

Well-capitalized cancer screening company developing multi-cancer early detection tests, backed by Illumina; represents a scaled competitor in the cancer screening category.

TypeEmerging player
Description

Multiomics platform for early cancer detection using AI on blood-based biomarkers; comparable as an AI-enabled cancer screening competitor with similar technology approach.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ONCOTECH LTD

Oncology AI Softwareoncotech.global

OncoTech Ltd is a London-based private company founded in 2019 that develops AI-based cancer screening technologies and oncology therapeutics. Public information on its products, operations, and commercialization is severely limited.

What ONCOTECH LTD does

OncoTech Ltd is a privately held UK-based company, founded in 2019 and headquartered in London. According to its firmographic profile, the company develops AI-based cancer screening technologies and oncology therapeutics, positioning it at the intersection of applied artificial intelligence and oncology drug development. The company maintains a web presence at oncotech.global, which targets a global audience via its top-level domain choice.

Beyond the high-level self-description, no verifiable information was available regarding OncoTech's specific product portfolio, underlying technology architecture, intellectual property holdings, funding history, management team, partnership network, customer base, revenue model, pricing, certifications, regulatory milestones, headcount, or go-to-market strategy. The company's own website (oncotech.global) was non-functional at the time of data collection, displaying only a loader/verification screen, and third-party data sources did not return substantive corporate, financial, or operational information. This combination of signals — a non-functional primary web presence combined with the absence of any corroborating data on funding, personnel, customers, or pipeline assets — implies either a very early/pre-commercial stage of development, limited public disclosure, or potential dormancy, and any investment-grade assessment will require primary-source verification of capitalization, pipeline status, and operational activity before substantive judgments can be made.

ONCOTECH LTD firmographics

Firmographics
Name
ONCOTECH LTD
Website
https://oncotech.global
Company type
Private
Founded year
2019
Headcount range
11–50 employees
Short description
OncoTech Ltd is a London-based private company founded in 2019 that develops AI-based cancer screening technologies and oncology therapeutics. Public information on its products, operations, and commercialization is severely limited.
Ownership category
akta.pro rank

ONCOTECH LTD industry classification

Industry
Product category
Oncology AI Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAB
Medical Oncology

Keywords

  • AI cancer screening
  • Oncology therapeutics
  • Cancer diagnostics
  • Medical AI software
  • Precision oncology

Where ONCOTECH LTD is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

ONCOTECH LTD business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel

ONCOTECH LTD product offering

Product offering

Core offering

OncoTech develops AI-based cancer screening technologies and oncology therapeutics. The company combines artificial intelligence with oncology to enable early cancer detection and advance therapeutic development for cancer patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI-based cancer screening technology Artificial intelligence-based cancer screening technology for early cancer detection, targeting healthcare providers and oncology stakeholders.
  • Oncology therapeutics Oncology therapeutics developed by OncoTech for cancer treatment, targeting oncology patients and healthcare providers.

Companies that use ONCOTECH LTD

Customer profile

Ideal customer profiles1 record

ONCOTECH LTD technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ONCOTECH LTD partnerships and signals

Strategic signal

Expansion highlights1 record

ONCOTECH LTD competitors and assessment

Company assessment

Direct peers

  • Owkin: AI biotech combining federated learning, diagnostics, and therapeutic development in oncology — closely aligned with OncoTech's positioning in Europe and its dual focus.
  • PathAI: AI pathology platform focused on cancer diagnostics and biomarker discovery, partnering with pharma for therapeutic development — closely aligned with OncoTech's dual screening + therapeutics scope.
  • Paige.AI: AI company applying deep learning to pathology and cancer diagnostics, with FDA-authorized products — a direct comparable for AI-based cancer screening technology.
  • Tempus AI: AI-driven precision medicine company combining multimodal data, diagnostics, and therapeutic insights in oncology — directly comparable to OncoTech's AI cancer screening and oncology therapeutics focus.
  • Exscientia: AI-driven drug discovery company with oncology pipeline, merged with Recursion — comparable for combining AI technology platform with proprietary therapeutic programs.
  • Recursion Pharmaceuticals: AI-native biopharma applying machine learning to drug discovery across oncology and other areas; comparable for its combination of AI technology platform with therapeutic development.

Broad incumbents

  • Foundation Medicine (Roche): Established leader in oncology molecular profiling and companion diagnostics, owned by Roche; represents the scaled incumbent in cancer screening/diagnostics that AI-driven players compete against.
  • Exact Sciences: Public diagnostics company with cancer screening products (Cologuard, Oncotype); represents an established incumbent in cancer screening that any AI-driven screening entrant must differentiate against.
  • GRAIL: Well-capitalized cancer screening company developing multi-cancer early detection tests, backed by Illumina; represents a scaled competitor in the cancer screening category.

Emerging players

  • Freenome: Multiomics platform for early cancer detection using AI on blood-based biomarkers; comparable as an AI-enabled cancer screening competitor with similar technology approach.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

ONCOTECH LTD social profiles

Digital presence

ONCOTECH LTD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ONCOTECH LTD leadership team

Management profile

Number of profiles

ONCOTECH LTD funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ONCOTECH LTD M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ONCOTECH LTD

What does ONCOTECH LTD do?

OncoTech develops AI-based cancer screening technologies and oncology therapeutics. The company combines artificial intelligence with oncology to enable early cancer detection and advance therapeutic development for cancer patients.

When was ONCOTECH LTD founded?

ONCOTECH LTD was founded in 2019. It employs 11 to 50 people.

Where is ONCOTECH LTD based?

ONCOTECH LTD is headquartered in London, United Kingdom, in the Europe region.

Who are ONCOTECH LTD's main competitors?

Direct peers on record are Owkin, PathAI, Paige.AI, Tempus AI, Exscientia and Recursion Pharmaceuticals. Broad incumbents are Foundation Medicine (Roche), Exact Sciences and GRAIL. Freenome is listed as an emerging player.

Does ONCOTECH LTD have an API?

No public API is recorded for ONCOTECH LTD.

What industry is ONCOTECH LTD in?

ONCOTECH LTD's product category is Oncology AI Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales